IL303265A - Combination immunotherapy of il-15 and cd40 agonist in cancer treatment - Google Patents

Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Info

Publication number
IL303265A
IL303265A IL303265A IL30326523A IL303265A IL 303265 A IL303265 A IL 303265A IL 303265 A IL303265 A IL 303265A IL 30326523 A IL30326523 A IL 30326523A IL 303265 A IL303265 A IL 303265A
Authority
IL
Israel
Prior art keywords
dose
per
body weight
agonist
melanoma
Prior art date
Application number
IL303265A
Other languages
English (en)
Hebrew (he)
Inventor
Jonas Vanaudenaerde
Evelien Smits
Marc Peeters
Original Assignee
Univ Antwerpen
Univ Ziekenhuis Antwerpen
Jonas Vanaudenaerde
Evelien Smits
Marc Peeters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Antwerpen, Univ Ziekenhuis Antwerpen, Jonas Vanaudenaerde, Evelien Smits, Marc Peeters filed Critical Univ Antwerpen
Publication of IL303265A publication Critical patent/IL303265A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL303265A 2020-12-04 2021-12-03 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment IL303265A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20211880 2020-12-04
PCT/EP2021/084265 WO2022117869A2 (en) 2020-12-04 2021-12-03 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Publications (1)

Publication Number Publication Date
IL303265A true IL303265A (en) 2023-07-01

Family

ID=73726649

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303265A IL303265A (en) 2020-12-04 2021-12-03 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Country Status (6)

Country Link
US (1) US20240010740A1 (de)
EP (1) EP4255463A2 (de)
AU (1) AU2021391637A1 (de)
CA (1) CA3203912A1 (de)
IL (1) IL303265A (de)
WO (1) WO2022117869A2 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170931A4 (de) * 2007-06-15 2010-06-30 Immurx Inc Verwendung von tlr-agonisten und/oder typ-1-interferonen zur verminderung der toxizität von therapeutischen protokollen mit tnf-r-agonisten
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
AU2021391637A9 (en) 2025-03-13
US20240010740A1 (en) 2024-01-11
WO2022117869A2 (en) 2022-06-09
AU2021391637A1 (en) 2023-07-06
EP4255463A2 (de) 2023-10-11
WO2022117869A3 (en) 2022-07-14
CA3203912A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
EP3394103B1 (de) Kombination aus anti-pd-1-antikörpern und bispezifischen anti-cd20/anti-cd3-antikörpern zur behandlung von krebs
JP6612252B2 (ja) 腫瘍特異的免疫応答の有効性を増強するための方法
MD3455259T2 (ro) Combinație de anticorpi anti-PD-1 și radiație pentru tratarea cancerului
US12122814B2 (en) Dual cytokine fusion proteins comprising IL-10
CN106687124B (zh) 并用il-18与分子靶向抗体的癌治疗药
US20240409600A1 (en) Dual cytokine fusion proteins comprising multi-subunit cytokines
EP3896089A1 (de) Verwendung von il-15-proteinkomplexen in verbindung mit pd-l1-antikörpern zur behandlung von tumorerkrankungen
CN110831629B (zh) 用于治疗癌症的包括abx196的组合
KR102239752B1 (ko) 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물
US20220411524A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
US20240009275A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
US20240010740A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
EP4342492A1 (de) Pharmazeutische kombination und verwendung davon
WO2026052074A1 (zh) 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用
HK40051088A (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
CN112439060A (zh) Pd-l1免疫疗法的新用途
HK1255040B (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer